• This topic is empty.
Viewing 0 reply threads
  • Author
    • #26806

      Fibrogen’s pamrevlumab drug has advanced to Phase 3 clinical trials. Its been proven to halt IPF disease progression and “ease fibrosis in IPF patients” in previous Phase 2 studies. Phase 3 will expand the number of people in the trials.

      Details are here:
      https://tinyurl.com/ipftrial (Pulmonary Fibrosis News article dated 1/6/2021)

      There are actually two phase 3 studies call ZEPHUS and ZEPHUS2. Both are actively recruiting IPF patients ages 40-85 who have been treated with Esbriet (pirfenidone) or Ofev (nintedanib) but stopped using them.

      IPf patients are being recruited for the ZEPHUS trial in the United States, Australia, Argentina, Taiwan, Chile, and the Republic of Korea. (Trial ID NCT03955146)

      IPF Patients for ZEPHUS2 are being recruited in Georgia, Italy, Hungary and Lebanon. (Trial ID NCT04419558)

      To view details of the trials, cities where clinics are and how to apply go:

      ZEPHUS https://clinicaltrials.gov/ct2/show/NCT03955146

      ZEPHUS2 https://clinicaltrials.gov/ct2/show/NCT04419558


Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account